JP2011511845A - アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物 - Google Patents

アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物 Download PDF

Info

Publication number
JP2011511845A
JP2011511845A JP2010546920A JP2010546920A JP2011511845A JP 2011511845 A JP2011511845 A JP 2011511845A JP 2010546920 A JP2010546920 A JP 2010546920A JP 2010546920 A JP2010546920 A JP 2010546920A JP 2011511845 A JP2011511845 A JP 2011511845A
Authority
JP
Japan
Prior art keywords
pyridinyl
methyl
azabicyclo
oct
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010546920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511845A5 (https=
Inventor
ベンチェリフ，メロウアン
ガット，グレゴリー，ジェイ．
ハウザー，テリー
ジー． ジョーダン，クリステン
アール． レッチワース，シャロン
Original Assignee
ターガセプト，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ターガセプト，インコーポレイテッド filed Critical ターガセプト，インコーポレイテッド
Publication of JP2011511845A publication Critical patent/JP2011511845A/ja
Publication of JP2011511845A5 publication Critical patent/JP2011511845A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2010546920A 2008-02-13 2009-02-13 アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物 Pending JP2011511845A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13
PCT/US2009/034062 WO2009102962A2 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics

Publications (2)

Publication Number Publication Date
JP2011511845A true JP2011511845A (ja) 2011-04-14
JP2011511845A5 JP2011511845A5 (https=) 2011-11-10

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010546920A Pending JP2011511845A (ja) 2008-02-13 2009-02-13 アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物

Country Status (25)

Country Link
US (1) US20110059947A1 (https=)
EP (2) EP2254598B1 (https=)
JP (1) JP2011511845A (https=)
KR (1) KR20100113163A (https=)
CN (2) CN103143023A (https=)
AU (1) AU2009214625A1 (https=)
BR (1) BRPI0907570A2 (https=)
CA (1) CA2715268A1 (https=)
CO (1) CO6290706A2 (https=)
CY (1) CY1114492T1 (https=)
DK (1) DK2254598T3 (https=)
EC (1) ECSP10010471A (https=)
ES (1) ES2430622T3 (https=)
HR (1) HRP20130749T1 (https=)
IL (1) IL207389A0 (https=)
MX (1) MX2010008875A (https=)
NZ (1) NZ587312A (https=)
PL (1) PL2254598T3 (https=)
PT (1) PT2254598E (https=)
RS (1) RS52941B (https=)
RU (1) RU2481123C2 (https=)
SG (1) SG188144A1 (https=)
SI (1) SI2254598T1 (https=)
WO (1) WO2009102962A2 (https=)
ZA (1) ZA201005999B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017195862A (ja) * 2016-04-29 2017-11-02 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
TW201242600A (en) * 2011-01-18 2012-11-01 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
WO2014054635A1 (ja) * 2012-10-02 2014-04-10 大日本住友製薬株式会社 イミダゾール誘導体
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2004052894A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US20050159597A1 (en) * 2003-12-22 2005-07-21 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
JP2006518746A (ja) * 2003-02-21 2006-08-17 ターガセプト，インコーポレイテッド ３−置換−２（アリールアルキル）−１−アザビシクロアルカンおよびこれらの使用方法
WO2006101745A2 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
JP2007516275A (ja) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
EP1083889B1 (en) 1998-06-01 2003-12-10 Ortho-McNeil Pharmaceutical, Inc. Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
CZ20021880A3 (cs) * 1999-12-10 2002-08-14 Wyeth Farmaceutický prostředek
CZ294251B6 (cs) * 2000-06-27 2004-11-10 Laboratorios S. A. L. V. A. T., S. A. Karbamáty a jejich použití pro výrobu farmaceutického prostředku
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
EP1311505A2 (en) 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2004052894A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
JP2006518746A (ja) * 2003-02-21 2006-08-17 ターガセプト，インコーポレイテッド ３−置換−２（アリールアルキル）−１−アザビシクロアルカンおよびこれらの使用方法
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US20050159597A1 (en) * 2003-12-22 2005-07-21 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
JP2007516275A (ja) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
WO2006101745A2 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017195862A (ja) * 2016-04-29 2017-11-02 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Also Published As

Publication number Publication date
MX2010008875A (es) 2010-08-31
RU2481123C2 (ru) 2013-05-10
PL2254598T3 (pl) 2013-12-31
WO2009102962A2 (en) 2009-08-20
RS52941B (sr) 2014-02-28
RU2010137787A (ru) 2012-03-20
EP2254598A2 (en) 2010-12-01
ES2430622T3 (es) 2013-11-21
CA2715268A1 (en) 2009-08-20
HRP20130749T1 (en) 2013-10-11
CO6290706A2 (es) 2011-06-20
SG188144A1 (en) 2013-03-28
BRPI0907570A2 (pt) 2019-09-24
IL207389A0 (en) 2010-12-30
CN103143023A (zh) 2013-06-12
US20110059947A1 (en) 2011-03-10
WO2009102962A3 (en) 2009-10-08
HK1147954A1 (en) 2011-08-26
ZA201005999B (en) 2011-05-25
EP2633868A1 (en) 2013-09-04
CY1114492T1 (el) 2016-10-05
NZ587312A (en) 2011-12-22
CN101977628A (zh) 2011-02-16
AU2009214625A1 (en) 2009-08-20
DK2254598T3 (da) 2013-07-29
PT2254598E (pt) 2013-10-16
KR20100113163A (ko) 2010-10-20
SI2254598T1 (sl) 2013-10-30
ECSP10010471A (es) 2010-10-30
EP2254598B1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
JP2011511845A (ja) アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
JP5595268B2 (ja) メタボリックシンドローム、２型糖尿病、肥満又は糖尿病前症の治療的処置方法
KR101754045B1 (ko) 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법
Bhattacharya et al. Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer’s disease mice
CN101631547A (zh) 使用地莫本和多奈哌齐治疗阿尔茨海默病的组合疗法
US20190105314A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
JP2012508765A (ja) ファルネシルトランスフェラーゼ阻害剤を使用するタンパク症の治療
CN106146391A (zh) 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
Mitsikostas et al. The 5-HT1F receptor as the target of ditans in migraine—from bench to bedside
KR20130101545A (ko) 운동 장애 치료를 위한 세로토닌 수용체 작용제의 조합
JP6910424B2 (ja) 掻痒症および／または痒みの治療方法
US12252457B2 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
US10736894B2 (en) Methods of treating developmental syndromes with PDE10A inhibitors
US20180289702A1 (en) Lpa level reduction for treating central nervous system disorders
JP2023550093A (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
HK1185794A (en) Combination of alpha 7 nicotinic agonists and antipsychotics
CN115385914B (zh) 靶向pdcd4的配体小分子在制备抗抑郁药物中的应用
JP5714572B2 (ja) 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法
HK1147954B (en) Combination of alpha 7 nicotinic agonists and antipsychotics
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト
Gallezot et al. 1. A Zebrafish Model for the functional analysis of genes in autism
ITRM20130522A1 (it) Trattamento e prevenzione per la sindrome di rett.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105